Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study
NCT ID: NCT06085456
Last Updated: 2023-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2021-09-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multi-omics Study of Epithelial Ovarian Cancer
NCT03742856
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
NCT05236686
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
NCT05410015
Genetic Mutation in Epithelial Ovarian Cancer
NCT04191252
An INternational Frontline Ovarian Cancer Real World Management Study
NCT04460768
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Patients from Renji Hospital were divided into training group and test group at a ratio of 7:3, and patients from Shanghai First Maternity and Infant Hospital were used as external validation group.
3. The training group was used to establish the diagnosis and prognosis prediction model of epithelial ovarian cancer, and the test group and the external validation group were used to verify the model, and the area under the ROC curve, accuracy, specificity, and sensitivity were used to evaluate the effect of the model.
4. For machine learning models, SHAP and LIME algorithms were used for model interpretation.
5. Unsupervised clustering algorithm was used to distinguish the subgroups of epithelial ovarian cancer patients, and KM was used to analyze the overall survival (OS) and progression-free survival (PFS) to predict the survival and recurrence of the subgroups. Overall survival (OS) was defined as the time from the first diagnosis of epithelial ovarian cancer to the confirmation of death or the end of follow-up. Progression-free survival (PFS) was defined as the time from the first diagnosis of epithelial ovarian cancer to the confirmation of disease progression or the end of follow-up.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EOC group
Patients diagnosed with epithelial ovarian cancer
Hematologic features
Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
Control group
Patients diagnosed with benign gynecological diseases, including ovarian cysts, uterine fibroids and uterine prolapse.
Hematologic features
Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hematologic features
Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age between 18 to 80 years old;
* complete preoperative blood routine test results, blood biochemical indicators, and tumor markers;
Exclusion Criteria
* patients with diagnosed tumors other than ovarian cancer;
* complicated with severe systemic diseases;
* pregnant or lactating women;
* patients diagnosed with recurrent epithelial ovarian cancer.
18 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aimin Zhao, MD
Role: PRINCIPAL_INVESTIGATOR
RenJi Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIT-2023-0202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.